● Recruiting

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Condition: Metastatic Pancreatic Neuroendocrine Tumor · Sponsor: University of Chicago

PhasePhase 1

Planned participants25

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Intake · 855-702-8222 · cancerclinicaltrials@bsd.uchicago.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06663072